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MaBACKGROUND The time course and extent of recovery after revascularization of viable dysfunctional myocardium are
variable. Although ﬁbrosis is a major determinant, myocyte structural and molecular remodeling may also play important
roles.
OBJECTIVES This study sought to determine whether persistent myocyte loss and/or irreversibility of protein changes
that develop in hibernating myocardium have an impact on functional recovery in the absence of infarction.
METHODS Swine implanted with a chronic left anterior descending artery (LAD) stenosis to produce hibernating
myocardium underwent percutaneous revascularization, with serial functional recovery evaluated for 1 month (n ¼ 12).
Myocardial tissue was evaluated to assess myocyte size, nuclear density, and proliferation indexes in comparison
with those of normal animals and nonrevascularized controls. Proteomic analysis by 2-dimensional differential in-gel
electrophoresis was used to determine the reversibility of molecular adaptations of hibernating myocytes.
RESULTS At 3 months, physiological features of hibernating myocardium were conﬁrmed, with depressed LAD wall
thickening and no signiﬁcant infarction. Revascularization normalized LAD ﬂow reserve, with no immediate change in LAD
wall thickening. Regional LAD wall thickening slowly improved but remained depressed 1 month post–percutaneous
coronary intervention. Surprisingly, revascularization was associated with histological evidence of myocytes re-entering
the growth phase of the cell cycle and increases in the number of c-Kitþ cells. Myocyte nuclear density returned to
normal, whereas regional myocyte hypertrophy regressed. Proteomic analysis demonstrated heterogeneous effects of
revascularization. Up-regulated stress and cytoskeletal proteins normalized, whereas reduced contractile and metabolic
proteins persisted.
CONCLUSIONS Delayed recovery of hibernating myocardium in the absence of scar may reﬂect persistent reductions
in the amounts of contractile and metabolic proteins. Although revascularization appeared to stimulate myocyte
proliferation, the persistence of small immature myocytes may have contributed to delayed functional recovery.
(J Am Coll Cardiol 2015;65:684–97) © 2015 by the American College of Cardiology Foundation.H ibernating myocardium is characterized byviable, dysfunctional myocardium that de-velops as an adaptive response to chronic
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AB BR E V I A T I O N S
AND ACRONYM S
CSC = cardiac stem cell
LAD = left anterior descending
artery
LADDWT = LAD wall
thickening (end-systolic L
end-diastolic wall thickness)
LV = left ventricular
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685(4), regional down-regulation of enzymes involved in
oxidative metabolism, and up-regulation of stress pro-
teins that allow the heart to adapt and prevent infarc-
tion (5). In some patients, these adaptations are
incomplete, and progressive ﬁbrosis and myocyte
loss develops. In others, these adaptations ultimately
minimize stress-induced ischemia, which prevents
further myocyte death, but at the expense of chronic
regional contractile dysfunction.SEE PAGE 698
PCI = percutaneous coronary
interventionAlthough contractile dysfunction in hibernating
myocardium can improve after revascularization,
complete recovery is infrequent (<25% of patients)
(6,7), and 1 in 4 dysfunctional segments without
ﬁbrosis (determined by magnetic resonance imaging)
fail to improve (8). The time course of functional
recovery is also variable. Different studies have
demonstrated rapid recovery (9), recovery within
several weeks (10–12), and delayed improvement
requiring 1 year (13–15). This protracted course
contrasts with the complete normalization of func-
tion within hours or days following acute stunning
and short-term hibernation (16). The roles of myo-
cyte loss (3) and myocardial protein changes (5,17)
in the delayed response to revascularization are
unclear.
We performed percutaneous revascularization of
swine with chronic hibernating myocardium to deter-
mine the initial time course of functional recovery
and the cellular mechanisms contributing to per-
sistent dysfunction in the absence of scar. We
demonstrated that revascularization of hibernat-
ing myocardium stimulated myocyte proliferation
(Central Illustration). Nevertheless, functional im-
provement was delayed and incomplete, with persis-
tent reductions in metabolic and contractile proteins 1
month after revascularization.TABLE 1 Hemodynamics in Revascularized and Nonrevascularized An
Heart Rate,
beats/min
LV Systolic
Pressure, mm Hg
LVEDP,
mm Hg
Revascularized
Baseline 108  4 108  14 28  3 2
2 h post-PCI 105  6 113  6 30  3 1
1 Month post-PCI 101  2 128  5 28  3 2
Nonrevascularized
Baseline 107  5 121  4 23  2 2
1 Month 103  5 120  4 23  2 2
Values are mean  SEM. Baseline measurements were made 3 months after surgical plac
LAD ¼ left anterior descending artery; LV ¼ left ventricular; LVEDP ¼ left ventricularMETHODS
Experimental procedures and protocols con-
formed to institutional guidelines for the care
and use of animals in research and were
approved by the University at Buffalo Insti-
tutional Animal Care and Use Committee.
CORONARY ARTERY INSTRUMENTATION.
Juvenile farm-bred pigs (8 to 10 kg) were
chronically implanted with a left anterior
descending artery (LAD) stenosis to produce
hibernating myocardium using a modiﬁcation of
previously published techniques (1). Fasted pigs
pre-medicated with tiletamine 50 mg/ml and zolaze-
pam 50 mg/ml (tiletamine)/ketamine 100 mg/ml
(0.037 ml/kg intramuscular [IM]), cefazolin 0.5 g
intravenous (IV), and gentamicin 40 mg IV were intu-
bated and anesthetized with isoﬂurane (1% to 2%).
A thoracotomy was performed in the fourth left inter-
costal space. The proximal LAD was implanted with
a short piece of expandable 1.5-mm internal diameter
silicone tubing with a longitudinal slit for vessel
insertion (18). It was secured with circumferential
sutures that could be expanded using standard an-
gioplasty balloon inﬂation pressures. The chest was
closed, intercostal nerves were inﬁltrated with 2%
lidocaine, and the pneumothoraxwas evacuated. Post-
operative antibiotics and analgesics (butorphanol
0.025 mg/kg) were administered as needed for pain.
SERIAL PHYSIOLOGICAL STUDIES AND PERCUTANEOUS
INTERVENTION. Pigs with hibernating myocardium
undergoing revascularization (n ¼ 12) were compared
with nonrevascularized animals (n ¼ 12) and normal
sham controls that underwent stent insertion (n ¼ 10).
Animals underwent baseline physiological studies at
approximately 3 months post-instrumentation in the
closed-chest sedated state (tiletamine/zolazepam/imals With Hibernating Myocardium
LV dP/dtMax,
mm Hg/s
LV dP/dtMin,
mm Hg/s
Regional Wall Thickening
WT, % DWT, mm
LAD Remote LAD Remote
,549  165 –2,467  148 38.6  4.0‡ 92.2  7.5 2.9  0.3‡ 5.8  0.3
,988  89* –2,247  125 35.2  4.6‡ 86.6  7.2 2.9  0.4‡ 5.7  0.4
,439  136† –2,514  96 58.6  4.9*‡ 86.9  6.9 4.6  0.4*‡ 6.3  0.3
,284  168 –2,225  154 34.0  2.1‡ 80.6  8.4 3.5  0.3‡ 6.1  0.4
,073  69 –2,184  139 26.5  3.2‡ 76.9  5.4 2.8  0.3‡ 7.2  0.5
ement of a LAD stenosis. *p < 0.05 versus baseline. †p < 0.05 versus 2 h post-PCI. ‡p < 0.05 LAD versus remote.
end-diastolic pressure; PCI ¼ percutaneous coronary intervention; WT ¼ wall thickening.
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686xylazine IM and propofol 2 to 5 mg/kg/min IV). Coro-
nary angiography was performed with a 5-F multi-
purpose catheter and nonionic contrast to quantify
stenosis severity and angiographic collaterals. Myo-
cardial perfusion was measured using ﬂuorescent
microspheres at rest and after adenosine vasodilation
(0.9 mg/kg/min, with coinfusion of phenylephrine
to prevent hypotension) (19). Regional function wasCENTRAL ILLUSTRATION Revascularization of Hibernatin
pHH3 Ki6
HIBERNATING
Page, B.J. et al. J Am Coll Cardiol. 2015; 65(7):684–97.
Delay in the functional recovery of hibernating myocardium is partly re
hypertrophy replaced by small new myocytes (upper panels). Immunoh
creases the number of proliferating myocytes (pHH3 and Ki-67 stains),measured using off-axis M-mode echocardiography
(Vivid 7, GE Healthcare, Little Chalfont, Buck-
inghamshire, United Kingdom) (19).
Percutaneous intervention (PCI) was performed
89  3 days after placement of the LAD stenosis.
Five days before the procedure, animals undergoing
PCI were pre-treated with clopidogrel (300 mg orally),
followed by daily aspirin (325 mg) and clopidogrelg Myocardium
cKit7
REVASCULARIZED
lated to stimulating new myocyte formation with myocyte cellular
istochemistry in the lower panels shows that revascularization in-
as well as c-Kitþ cardiac stem cells. pHH3 ¼ phospho-histone H3.
FIGURE 1 Selected Angiographic Images From an Animal With Hibernating Myocardium
Pre-PCI 2 Hours Post-PCI 1 Month Post-PCI
The pre-PCI image demonstrates a severe proximal LAD stenosis. The 2-h post-PCI image demonstrates a widely patent LAD, with no signiﬁcant restenosis after 1 month.
LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex artery; OM ¼ obtuse marginal; PCI ¼ percutaneous coronary intervention.
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687(75 mg). After heparin (5,000 U IV), a 6-F guiding
catheter was inserted and a 0.014-inch guide wire
advanced into the LAD. If total LAD occlusion
was present, pre-dilation was performed with aFIGURE 2 Coronary Flow Reserve and Regional Wall
Thickening in Hibernating Myocardium Before and
Immediately After PCI
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LAD subendocardial ﬂow reserve (A) and wall thickening (B)
were reduced in hibernating myocardium (pre-PCI). Flow reserve
normalized 2 h later (post-PCI), but LAD wall thickening
remained depressed. Abbreviations as in Figure 1.low-proﬁle balloon. Subsequently, percutaneous re-
vascularization was performed with a bare-metal
stent (Multi-Link Zeta, Abbott Vascular, Santa Clara,
California) placed in most animals (n ¼ 9) to prevent
recoil of the Silastic stenosis.
Flow and function were reassessed 2 h after revas-
cularization. To deﬁne the time course of functional
recovery, animals were brought back for serial echo-
cardiography at 1 day, 3 days, 1 week, and 1 month.FIGURE 3 Delayed Time Course of Functional Improvement After PCI
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Regional wall thickening was reduced at rest (pre-PCI). There was no imme-
diate effect of revascularization, but a delayed improvement in function
became evident after 1 week. No further functional improvement occurred at
1 month, and LAD wall thickening remained depressed. Abbreviations as in
Figure 1.
TABLE 2 Proteomic Proﬁling in Swine With Hibernating Myocardium With and
Without Revascularization*
Protein Name n
Average Ratio
Hibernating
LAD/Sham
Revascularized
LAD/Sham
Citric acid cycle proteins
Pyruvate dehydrogenase E1 alpha subunit 12 0.68† 0.74
Pyruvate dehydrogenase E1 beta subunit 12 0.60† 0.77†‡
Dihydrolipoamide acetyltransferase (PDH E2) 12 0.74† 0.85†‡
Dihydrolipoamide dehydrogenase (PDH E3) 12 0.86 0.87
Dihydrolipoamide dehydrogenase (PDH E3) 12 0.77† 0.79
Aconitase 10 1.28† 1.05‡
Aconitase 12 1.06 1.05
Aconitase 12 0.86 0.98
Aconitase 9 0.95 0.81
Aconitase 11 1.00 1.18
NADþ isocitrate dehydrogenase (alpha subunit) 12 0.69† 0.75†
NADþ isocitrate dehydrogenase (alpha subunit) 12 0.72† 0.83†‡
Dihydrolipoamide succinyltransferase 12 0.87 0.96
Dihydrolipoamide succinyltransferase 11 0.97 1.02
Malate dehydrogenase (mitochondrial) 11 0.77 0.91‡
Malate dehydrogenase (mitochondrial) 9 0.85 0.91
Malate dehydrogenase (mitochondrial) 12 0.84 0.91
Electron transport chain and ATP synthesis proteins
NADH dehydrogenase (complex I) 75-kDa subunit 12 0.86 0.84
NADH dehydrogenase (complex I) 75-kDa subunit 11 0.72 0.76
NADH dehydrogenase (complex I) 51-kDa subunit 12 0.82 0.89
NADH dehydrogenase (complex I) 51-kDa subunit 12 0.67† 0.79†‡
NADH dehydrogenase (complex I) 30-kDa subunit 10 0.61† 0.62†
NADH dehydrogenase (complex I) 24-kDa subunit 11 0.78 0.88
Flavoprotein subunit of complex II 12 0.58† 0.74‡
Cytochrome Bc1 core protein I (complex III) 12 0.69† 0.95‡
ATP synthase F1 alpha chain 7 0.87 1.00
ATP synthase F1 alpha chain 7 0.91 0.94
ATP synthase F1 alpha chain 12 0.86 0.89
ATP synthase F1 alpha chain 12 0.71† 0.81
ATP synthase F1 beta chain 12 1.20 0.91‡
ATP synthase F1 beta chain 12 0.84 0.77†
Fatty acid oxidation proteins
Medium-chain acyl-CoA dehydrogenase 12 0.88 0.80
Long-chain acyl-CoA dehydrogenase 12 0.84 0.81‡
Other mitochondrial matrix proteins
60-kDa heat shock protein, mitochondrial 12 0.95 0.94
Aspartate aminotransferase, mitochondrial 8 1.07 1.05
Creatine kinase, mitochondrial 6 1.01 0.96
Creatine kinase, mitochondrial 12 0.80 0.78
Isovaleryl-CoA dehydrogenase 12 0.78 0.82
Mitochondrial stress 70 protein (GRP75) 12 0.92 0.98
NADPþ isocitrate dehydrogenase (47-kDa subunit) 11 0.58† 0.77‡
NADPþ isocitrate dehydrogenase (47-kDa subunit) 11 0.62 0.76‡
Succinyl-CoA 3-ketoacid-CoA transferase 1 12 0.69† 0.78†
Translation elongation factor EF-Tu 12 0.76† 0.84
Other mitochondrial membrane proteins
Mitoﬁlin 10 1.07 1.23
Mitoﬁlin 12 0.78† 0.95
Prohibitin 3 0.83 0.95
Voltage-dependent anion channel 2 12 0.70† 0.96‡
Voltage-dependent anion channel 1 8 0.85 0.93
Voltage-dependent anion channel 1 12 0.87 0.97
Continued on the next page
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688Angiography and ﬂow measurements were repeated
at 1 month, after which animals were euthanized
under general anesthesia 72 h later. Hearts were
stained with triphenyltetrazolium chloride (TTC) to
exclude infarction, and samples were obtained for
histology.
PROTEOMIC PROFILING. Samples for proteomics
taken from the LAD subendocardium were immedi-
ately ﬂash-frozen at 80C. We used 2-dimensional
differential in-gel electrophoresis (2D-DIGE) to assess
protein expression, using published techniques (5,17),
as described in the Online Appendix. Total protein
extracted from hibernating swine that were revas-
cularized (n ¼ 12) and nonrevascularized (n ¼ 12)
were compared with a pooled sham control sample
(5). Samples were labeled with CyDye DIGE ﬂuor,
run on 2D gels, scanned, and imported into DeCyder
version 6.5 software (GE Healthcare) for gel matching
and analysis. Spot identiﬁcation was performed
by in-gel trypsin digestion, matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrom-
etry (Mascot search engine), and liquid chromato-
graphy (LC)/mass spectrometry (MS) (Bioworks
software and SEQUEST). A heat map was created
to compare proteins identiﬁed as dysregulated in
hibernating myocardium in animals with and
without revascularization (R package version 2.13.0
[20]). Selected enzyme activities were assayed as
described (5).
MYOCYTE NUCLEAR DENSITY AND MORPHOMETRY.
Myocyte nuclear density was quantiﬁed using he-
matoxylin and eosin–stained sections (3). Periodic
acid–Schiff–stained sections were used to quantify
myocyte diameter (100 longitudinal myocytes per
region) in revascularized (n ¼ 12), nonrevascularized
(n ¼ 8), and sham normal (n ¼ 6) samples (19).
Myocytes were included regardless of size, as long as
myoﬁlaments could be identiﬁed surrounding the
nucleus.
IMMUNOHISTOCHEMICAL ASSESSMENT OF MYOCYTE
PROLIFERATION. Parafﬁn-ﬁxed tissue sections (app-
roximately 4-mm thickness) were incubated with anti–
Ki-67 (mouse monoclonal antibody, clone MIB-1,
1:200, Dako, Carpinteria, California) or anti–phospho-
histone-H3 (rabbit polyclonal antibody, 1:1,000, Up-
state Biotech, Lake Placid, New York) and costained
with anti-cTnI (rabbit polyclonal antibody, 1:200,
Santa Cruz Biotechnology, Dallas, Texas) to conﬁrm
colocalization in myocytes (19,21). Myocardial c-Kitþ/
CD45 cells (both antibodies 1:200 dilution, AbD-
Serotec, Raleigh, North Carolina) and c-Kitþ/GATA4þ
cells (1:200 dilution, Santa Cruz Biotechnology) were
TABLE 2 Continued
Protein Name n
Average Ratio
Hibernating
LAD/Sham
Revascularized
LAD/Sham
Glycolytic proteins
Fructose biphosphate aldolase A 7 0.61 0.78
Fructose biphosphate aldolase A 11 0.67 0.87‡
Triosephosphate isomerase 12 0.67† 0.73†
Triosephosphate isomerase 12 0.99 0.83†‡
GAPDH 11 1.58 1.19‡
GAPDH 12 1.27 0.93‡
GAPDH 12 0.96 0.77‡
GAPDH 8 1.05 0.87‡
Phosphoglycerate kinase 1 6 0.67† 0.90‡
Phosphoglycerate mutase 2 M isozyme 12 0.70† 0.71†
Enolase 3 12 0.94 0.90
Alpha enolase 11 0.98 1.09
Beta enolase 12 0.84 0.86
Muscle speciﬁc phosphopyruvate hydratase
(enolase)
12 0.81† 0.77†
Pyruvate kinase 12 0.66† 0.86
Anaerobic metabolism proteins
L-lactate dehydrogenase B chain 6 0.64† 0.68†
L-lactate dehydrogenase B chain 12 0.68† 0.89‡
Contractile proteins
Actin, alpha-cardiac 12 0.83 0.89
Actin, alpha-cardiac 12 1.20 1.01‡
Actin, alpha-cardiac 3 0.80 0.71
Actin, alpha-cardiac 11 1.03 0.86
Actin, alpha-cardiac 12 0.65† 0.86‡
Actin, alpha-cardiac 11 0.45† 0.57†‡
Actin, alpha-cardiac 8 0.58† 0.78‡
Actin, alpha-cardiac 10 0.92 0.77†‡
Myosin heavy chain alpha (cardiac) 11 0.99 0.92
Myosin heavy chain alpha (cardiac) 10 0.66† 1.29
Myosin heavy chain beta 8 0.69 0.95
Myosin heavy chain beta 6 0.77 0.88
Myosin heavy chain beta 6 0.92 1.08
Myosin heavy chain beta 3 1.20 0.84
Myosin heavy chain beta 12 0.94 0.95
Myosin heavy chain beta 9 0.87 1.36
Myosin heavy chain beta 4 1.46 1.11
Myosin heavy chain beta 3 1.14 1.05
Myosin heavy chain beta 9 1.23 1.07
Myosin light chain 3 11 0.65† 0.71†
Myosin light chain 3 11 0.60† 0.67†
Myosin light chain 3 11 0.83† 0.74†
Troponin T, cardiac 6 0.69 0.86‡
Troponin T, cardiac 12 0.70† 0.74†
Troponin T (cardiac isoform type 2) 12 0.67† 0.71†
Troponin T, cardiac 12 0.73† 0.60*‡
Troponin T cardiac 12 0.74† 0.64*‡
Tropomysin alpha chain 11 0.82 0.81
Tropomysin beta chain 12 0.61† 0.63†
Continued on the next page
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689quantiﬁed in frozen sections (19,21), post-treated
with ﬂuorescein isothiocyanate–conjugated anti-
mouse and TexasRed-conjugated anti-rabbit anti-
bodies (Dako). Nuclei were stained with TO-PRO-3
(Life Technologies, Grand Island, New York) or
4’,6-diamidino-2-phenylindole (Vectashield, Vector
Laboratories, Burlingame, California). Image acqui-
sition was performed with a confocal microscope
(MRC 1024, Bio-Rad, Hercules, California) and an
ApoTome-equipped AxioImager (Zeiss, Thornwood,
New York). Results represent means of 363  25 ﬁelds
(57  4 mm2).
STATISTICS. Data are expressed as mean  SEM
(SigmaStat 3.0, SPSS, Systat Software Inc., San Jose,
California). Within-group comparisons over time and
comparisons between hibernating and normally
perfused remote regions were assessed using paired
Student t tests. Between-group differences were
assessed using a 2-way analysis of variance (ANOVA)
and the post-hoc Holm-Sidak test. An unpaired Stu-
dent t test was used for statistical analysis of prote-
omics data, and a 1-way ANOVA was used for analysis
of enzyme activity data.
RESULTS
TEMPORAL FUNCTIONAL IMPROVEMENT AFTER
REVASCULARIZATION. Serial angiographic images
from an animal with hibernating myocardium are
displayed in Figure 1. Revascularized and non-
revascularized animals exhibited slight differences in
stenosis severity (93%  2% vs. 99%  1%; p < 0.05)
but similar reductions in subendocardial LAD ﬂow
reserve (2.0  0.5 vs. 2.1  1.3; p ¼ 0.93) and LAD wall
thickening (LADDWT) (2.9  0.3 mm vs. 3.5  0.3 mm;
p ¼ 0.17). Restenosis 1 month after PCI was insigniﬁ-
cant (23%  5%). TTC staining showed <1% infarction,
and LAD connective tissue was similar (9.8  1.3% vs.
7.9  0.9% after PCI; p ¼ 0.28).
Hemodynamics and measurements of regional wall
thickening are summarized in Table 1. Indexes of
global function were normal at all time points and are
summarized in Online Table 1. Despite immediate
normalization of LAD ﬂow reserve (Figure 2), wall
thickening initially remained unchanged (LADDWT
2.9  0.4 vs. 2.9  0.3 mm; p ¼ 0.77). Regional LAD
function gradually increased in the ﬁrst week
following revascularization and became signiﬁcant
after 1 week (LADDWT 2.9  0.3 to 4.2  0.4 mm;
p < 0.05) (Figure 3). There was little additional
improvement thereafter and, despite complete
revascularization, LAD dysfunction persisted at 1
month (LADDWT 4.6  0.4 vs. 6.3  0.3 mm in
remote; p < 0.05).THE EFFECTS OF REVASCULARIZATION ON THE
HIBERNATING MYOCARDIUM PROTEOME. Table 2
summarizes the effects of revascularization on pro-
teomic adaptations in hibernating myocardium
TABLE 2 Continued
Protein Name n
Average Ratio
Hibernating
LAD/Sham
Revascularized
LAD/Sham
Structural/cytoskeletal proteins
Actin-interacting protein 12 0.79 0.97‡
Desmin 12 1.23 1.21
Desmin 11 1.14 0.87‡
Desmin 12 1.34† 0.90‡
Desmin 10 0.85 1.44
Desmin 12 1.37† 0.93‡
Gelsolin precursor 11 1.42 1.21
Vimentin 12 1.54† 1.10‡
Vinculin 12 1.14 1.09
Stress proteins
Alpha,beta crystalline 12 1.50† 0.90‡
AlphaB crystalline 12 0.90 0.70†‡
Annexin 2 5 1.24 1.29
Annexin 2 12 1.05 1.04
GRP78 12 1.29 0.99‡
GRP78 12 1.22† 1.17
HSP70 (70-kDa protein 1) 12 1.11 0.99‡
HSP70 (70-kDa protein 1) 12 0.83 0.96‡
HSP60 12 0.95 0.94
HSP27 12 1.39 0.99
HSP27 12 1.07 0.91
HSP27 4 1.07 0.85
HSP20 beta-6 12 1.69† 0.73†
T-complex protein 1 (chaperonin) 12 0.88 0.87
Antioxidant proteins
Peroxiredoxin 2 12 0.90 0.87
Peroxiredoxin 6 12 0.73† 0.75†
Other cytoplasmic proteins
Aconitase 1 (iron regulatory protein 1) 11 0.97 1.06
Aminoacylase 1 5 0.55† 0.68‡
Aspartate aminotransferase (cytoplasmic) 12 0.52† 0.64†
Creatine kinase, M chain (cytoplasmic) 11 0.84 0.69†‡
Creatine kinase, M chain (cytoplasmic) 12 0.73† 0.71†
Creatine kinase, M chain (cytoplasmic) 12 0.56† 0.65†
Cytosolic aminopeptidase 12 1.00 0.97
Dihydropyrimidinase-related protein 2 12 0.87† 0.83†
Malate dehydrogenase (cytoplasmic) 12 0.64† 0.69†
Myoglobin 8 0.62 0.61
Myoglobin 10 0.43† 0.36†
Transitional endoplasmic reticulum ATPase 11 0.99 1.04
Endoplasmic reticulum proteins
Protein disulﬁde isomerase A3 12 1.04 1.06
*Italicized proteins are depicted in Figure 5. †p < 0.05 versus sham. ‡p < 0.05 versus hibernating.
Abbreviation as in Table 1.
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690(5,17,22), and proteins correlating with increases in
ﬂow and function after revascularization are sum-
marized in the heat map (Figure 4). Figure 5 summa-
rizes average changes in selected proteins from each
category (proteins italicized in Table 2). In general,
reductions in the levels of contractile proteins andmetabolic enzymes persisted after revascularization.
NADH dehydrogenase (42- and 30-kDa subunits), ATP
synthase (F1 alpha and beta chains), pyruvate
dehydrogenase (E1 alpha, dihydrolipoamide dehy-
drogenase), and isocitrate dehydrogenase remained
down-regulated, whereas the levels of long-chain
acyl-CoA dehydrogenase decreased. The levels of
the 51-kDa subunit of NADH dehydrogenase, ﬂavo-
protein subunit of complex II, cytochrome Bc1 core
protein 1, pyruvate dehydrogenase (E1beta and E2),
malate dehydrogenase, and medium-chain acyl-CoA
dehydrogenase increased but did not completely
normalize. Cytochrome c oxidase and citrate syn-
thase activities, which were reduced in hibernating
myocardium, corroborated the heterogeneous ef-
fects of revascularization on metabolic enzymes
(Figure 6).
Despite variable effects of revascularization on
metabolic enzymes, alleviation of repetitive ischemia
by PCI normalized the levels of cytosolic stress and
structural proteins (Figures 4 and 5). Stress proteins
including alpha,beta-crystalline, GRP78, and HSP20,
as well as structural proteins such as vimentin and
desmin, were no longer up-regulated. Revasculariza-
tion had limited effects on contractile proteins, with
most levels that were reduced in hibernating myo-
cardium remaining so after revascularization. This
failure to reverse chronic reductions in contractile
and metabolic protein levels may contribute to
persistent dysfunction and delayed functional re-
covery of hibernating myocardium.
REVASCULARIZATION STIMULATES MYOCYTE
PROLIFERATION IN HIBERNATING MYOCARDIUM.
We evaluated the effects of revascularization on
myocyte number (nuclear density) and cell diameter
(Figure 7). Nonrevascularized animals exhibited
regionally reduced nuclear density and increased
myocyte diameters, as we previously reported in
hibernating myocardium (3). In contrast, we found
a prominent increase in LAD nuclear density
(998  52 to 1,406  103 myocyte nuclei/mm2;
p < 0.05) 1 month after revascularization, with
smaller-diameter cardiomyocytes (10.3  0.3 mm vs.
15.7  0.5 mm; p < 0.05). Despite these prominent
changes, LAD end-diastolic wall thickness was
unchanged after revascularization (7.8  0.4 mm
to 8.2  0.6 mm; p ¼ 0.63). The relative increase
in end-diastolic wall thickness of 4.7  4.1 % was
similar to the 6.0  2.4% change observed in non-
revascularized animals (p ¼ 0.28).
To explain the increased myocyte nuclear density,
we evaluated the effects of revascularization on in-
dexes of myocyte proliferation. The levels of Ki-67, a
FIGURE 4 Heat Map Demonstrating Differential Expression of Proteins Correlating With Increased Flow and/or Function From Animals With
Hibernating Myocardium
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Following revascularization and the alleviation of ischemia, up-regulated (red) stress and cytoskeletal proteins and glycolytic enzymes generally normalized (yellow).
In contrast, many metabolic and contractile protein levels remained depressed (green) 4 weeks after revascularization. Abbreviation as in Figure 1.
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691marker of cell cycling, and the mitotic marker,
phospho-histone-H3 (pHH3), were no different in LAD
myocytes from sham and nonrevascularized animals.
In contrast, the levels of Ki-67 increased from 410 
82 to 2,109  400 nuclei/106 myocyte nuclei after
revascularization (Figure 8A). Likewise, myocyte
pHH3 levels increased from 9  5 to 350  50 nuclei/
106 myocyte nuclei (Figure 8B). Resident cardiac stem
cells (LAD c-Kitþ/CD45 cells) (Figure 8C) were rare in
shams (20  11 cells/106 myocyte nuclei; n ¼ 6), butthe levels tended to be higher in hibernating
myocardium (178  59 cells/106 myocyte nuclei; n ¼ 7;
p ¼ 0.052), with signiﬁcant increases 1 month after
revascularization (401  43 cells/106 myocyte nuclei;
n ¼ 6; p < 0.05). Progenitor cells committed to a car-
diac lineage (c-Kitþ/GATA4þ) were not detected in
shams but were present in hibernating myocardium
(15  10 cells/106 myocyte nuclei; p < 0.05 vs. sham)
and 1 month after revascularization (43  20 cells/106
myocyte nuclei; p < 0.05 vs. sham; p ¼ 0.38 vs.
FIGURE 5 Summary of Selected Proteins From 2-Dimensional Differential In-Gel Electrophoresis
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FIGURE 6 Variable Effects of Revascularization on Enzymatic Activity
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FIGURE 7 Effect of PCI on Myocyte Diameter and Nuclear Density in
Hibernating Myocardium
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693hibernating myocardium). The increased proliferative
indexes, reductions in myocyte size, and increased
myocyte nuclear density collectively support the
notion that revascularization stimulated new myo-
cyte formation in hibernating myocardium.
DISCUSSION
Despite complete revascularization of chronic hiber-
nating myocardium and the absence of scar, there
was no immediate improvement in regional LAD wall
thickening. Although it improved 1 week after revas-
cularization, there was little subsequent improve-
ment, and it remained depressed 1 month later.
Tissue analysis at this time point demonstrated vari-
able effects of revascularization on the proteome.
Up-regulated stress and cytoskeletal proteins nor-
malized, but reductions in the levels of contractile,
metabolic, and mitochondrial proteins persisted.
Unexpectedly, revascularization stimulated myo-
cyte proliferation. These results suggest that the
prolonged time course required for functional
improvement in some patients with viable dysfunc-
tional myocardium reﬂects heterogeneous effects of
revascularization on the myocardial proteome, as
well as the potentially time-dependent maturation of
small, newly formed cardiomyocytes.
T IME COURSE OF FUNCT IONAL RECOVERY
FOLLOWING REVASCULARIZATION. Patients with
viable dysfunctional myocardium display consider-
able variability in the magnitude and time course
of functional recovery after revascularization (13,14).
This is in part due to variable degrees of ﬁbrosis
and subendocardial infarction, but even completely
viable myocardium exhibits variability. This likely
reﬂects the underlying mechanisms of dysfunction,
which arise from reversible ischemia (acute stun-
ning, chronic stunning, and chronic hibernating
myocardium) (23). The spectrum of viable dysfunc-
tional myocardium leads to heterogeneity in the
extent of myocyte loss (3,24) and variability in
chronic molecular adaptations induced in response
to reversible ischemia (5,17). We previously demon-
strated that similar degrees of chronic contractile
dysfunction from a chronic stenosis result in vari-
able degrees of myocyte loss and proteomic re-
modeling (17,24). These variations are related to
physiological stenosis severity, with more profound
abnormalities developing in hibernating myocar-
dium where coronary ﬂow reserve becomes critically
impaired.
Our results in swine with chronic hibernating
myocardium excluded infarction as a covariate and
FIGURE 8 Revascularization of Hibernating Myocardium Increases the Number of
c-Kitþ Cells, Ki-67þ Myocytes, and pHH3þ Myocytes
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(A) Confocal images of Ki-67þ staining (green) in a myocyte (cardiac troponin I) (red) and
nonmyocyte after revascularization. Nuclei are stained with 4’,6-diamidino-2-phenylindole
(blue). Revascularization signiﬁcantly increased the number of Ki-67þ myocytes, consis-
tent with increased DNA synthesis. (B) Confocal images depicting a pHH3þ nucleus
(green), indicating a myocyte undergoing mitosis. Revascularization increased the number
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dium and sham controls. (C) Confocal images of a c-Kitþ cell between cardiomyocytes. The
number of myocardial c-Kitþ cells increased after revascularization. PCI ¼ percutaneous
coronary intervention; pHH3 ¼ phospho-histone H3.
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694demonstrated several phases of functional recovery
(Figure 3). Despite complete restoration of perfusion,
there was no immediate change in function nor
did function increase in the ﬁrst several days after
revascularization. A signiﬁcant, but delayed, in-
crease in LADDWT was observed 1 week later. This
early time course is reminiscent of the normalization
seen following short-term hibernation (16,23). No
further functional improvement occurred up to 1
month later. This delay in functional recovery con-
trasts with prior animal models (18,25,26), in which
dysfunction was not as chronic and resting function
normalized early (within 1 to 2 weeks after revas-
cularization). Thus, the present ﬁndings are more
compatible with clinical observations following
revascularization in chronic ischemic cardiomyo-
pathy, in which function rarely normalizes and
frequently requires 3 to 12 months to reach a new
steady state (13).
INCOMPLETE PROTEOMIC REMODELING AFTER
REVASCULARIZATION. We previously demonstrated
a spectrum of proteomic abnormalities in viable
dysfunctional myocardium that progress as stenosis
severity increases (17). Proteomic changes in non-
revascularized animals with hibernating myocar-
dium were characterized by down-regulation of
multiple mitochondrial proteins, including enzymes
that are entry points to oxidative metabolism (e.g.,
pyruvate dehydrogenase and acyl-CoA dehydroge-
nase), down-regulation of contractile proteins, and
up-regulation of stress and cytoskeletal proteins,
as previously described (5,27). Other investigators
have shown that up-regulated stress and cytoskeletal
proteins normalize 1 month after revascularization,
accompanied by reductions in the amount of inter-
stitial connective tissue (26,28). In contrast, revas-
cularization had only modest effects on metabolic
enzyme levels, and reductions in contractile protein
levels persisted. We previously demonstrated that
regional metabolic protein levels and mitochondrial
oxygen consumption progressively decline as stenosis
severity increases in viable dysfunctional myocar-
dium (5,17,22,29). Consonant with our ﬁndings,
Kelly et al. (25) reported persistent reductions in the
mitochondrial proteome before and after surgical
revascularization of hibernating myocardium. Never-
theless, resting contractile function normalized
1 month post-revascularization (25). In their study,
attenuation of the ﬂow and functional responses
to dobutamine persisted, suggesting that mitochon-
drial dysfunction continued to limit oxygen con-
sumption during beta-adrenergic stimulation (30,31).
This attenuated response could also reﬂect
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695persistent regional sympathetic denervation and
reduced beta-adrenergic responsiveness, despite
revascularization (18,32,33).
STIMULATION OF MYOCYTE REGENERATION BY
REVASCULARIZATION. An unexpected ﬁnding was
the prominent reverse myocyte remodeling induced
by restoring perfusion to hibernating myocardium.
This has not been evaluated in patients because it
would require serial left ventricular (LV) biopsies
after revascularization. Consonant with previous
studies, nonrevascularized animals with hibernating
myocardium had reductions in myocyte nuclear
density and compensatory cellular hypertrophy that
maintained near normal regional wall thickness in the
face of apoptosis (3,21). Revascularization increased
myocyte nuclear density and reduced cellular hy-
pertrophy, despite LAD wall thickness remaining
unchanged. Myocyte proliferation after revasculari-
zation was suggested by immunohistochemistry of
myocytes in the synthetic phase of the cell cycle using
Ki-67 and increases in the levels of myocyte mitotic
marker, phospho-histone-H3. Previous studies in this
model have shown that myocyte apoptosis returns to
low values (approximately 0.003%) during the time
period in which experiments were performed in the
present study (19). Thus, proliferation indexes were
1 to 2 orders of magnitude higher than myocyte
apoptosis at this time, resulting in a net increase
in myocyte number. These ﬁndings suggest that
de novo myocyte formation with delayed maturation
may contribute to delayed functional recovery. The
observation that revascularization stimulates new
myocyte formation is also reinforced by recent clin-
ical observations. First, some patients with revers-
ible dyssynergic myocardium have regional wall
thinning that reverses after revascularization (34).
Although originally thought to indicate irrevers-
ibility from infarction, some of these regions develop
profound increases in wall thickness and systolic
function after revascularization. Revascularization
might plausibly have stimulated endogenous myo-
cyte proliferation. Secondly, D’Amario et al. (35)
recently isolated cardiac stem cells (CSCs) from bi-
opsies obtained from patients undergoing coronary
bypass surgery and demonstrated that CSC prolifer-
ation and function in vitro correlated with late
functional improvement after revascularization.
Increased telomere length and reduced population
doubling time in c-Kitþ CSCs predicted increased
wall thickness, increased LV mass, and increases in
LV ejection fraction 12 months after revasculariza-
tion. Our results are compatible with these clinical
observations, but a limitation relates to our inabilityto determine whether the new myocytes arose from
the increase in the number of c-Kitþ CSCs or from
the proliferation of existing myocytes; experimental
evidence is available to support (36) and to refute
(37) c-Kitþ cells as a source of new myocytes.
Elucidating the answer will require sophisticated
approaches to study endogenous myocyte fate,
which currently are largely conﬁned to transgenic
animal studies. Regardless of their source, our ﬁnd-
ings suggest that new myocyte formation and/or
maturation may delay functional recovery after
revascularization.
STUDY LIMITATIONS. Farm-bred pigs require 3 to 4
months to develop hibernating myocardium and, due
to their size, could only be studied for 1 month after
revascularization in our facility. Although this study
provided new insight into the factors responsible for
persistent dysfunction, we cannot assess long-term
functional recovery, proteomic remodeling, or myo-
cyte proliferation. Thus, it is uncertain whether
regional function would completely recover over a
longer follow-up period and whether changes in
protein expression would normalize. Mini-swine (31)
may facilitate longer-term studies of coronary revas-
cularization. Likewise, young healthy animals may
have more plasticity in myocyte regeneration than
humans with disease, which could also signiﬁcantly
impact the extent of functional recovery and
remodeling.
Our results demonstrated that revascularization
elicited a signiﬁcant increase in myocyte number and
reciprocal reduction in myocyte size. Although these
new myocytes appear to be consistent with new
myocyte formation, it is unclear if they would
continue to increase in size and ultimately develop
into functionally mature cardiomyocytes over a
longer follow-up period. In this case, the delayed
time course of new myocyte maturation may
contribute to the delayed recovery of contractility
after PCI. However, if the myocytes remain small and
immature, their long-term contribution to contractile
function may be limited (38,39). Future studies with a
longer follow-up period are necessary to deﬁnitively
address this question.
Finally, proteomics involves the parallel analysis of
multiple proteins on a 2-dimensional gel, which can
lead to false discovery of differential protein ex-
pression via type I errors (40). These can be mini-
mized using large samples, as employed in our study,
which reduces the impact of biological and ex-
perimental variability. Nearly all protein changes
in nonrevascularized animals were previously re-
ported in independent experiments using the same
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
patients with ischemic cardiomyopathy, improvement
in ventricular function after revascularization may be
delayed as a consequence of chronic cellular protein
adaptations to repetitive ischemia and immature car-
diomyocyte formation, even in zones of viable
myocardium.
TRANSLATIONAL OUTLOOK: Beyond alleviating
ischemia through revascularization, the efﬁcacy of
hybrid interventions that concurrently accelerate
endogenous myocyte formation to enhance functional
recovery of hibernating myocardium warrants further
study.
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696experimental approach in this model and in an
expanded protein analysis using label-free quantiﬁ-
cation with LC/MS (22).
CONCLUSIONS
Our study demonstrated that, even in the absence of
infarction, the delayed improvement in LV function
after revascularization of hibernating myocardium
was associated with an incomplete reversal of the
molecular phenotype and the stimulation of new
cardiomyocytes originally lost via regional apoptosis
from reversible ischemia. Thus, adjunctive treat-
ments, such as intracoronary stem cells (21) and
growth factors (19), may accelerate functional recov-
ery following revascularization of high-risk patients
with heart failure, as well as those in whom complete
revascularization is not technically feasible. Studies
evaluating hybrid strategies to treat viable dysfunc-
tional myocardium will be needed to test these
hypotheses.
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